Medscape Global Oncology

Gene Therapy for Hemophilia A

What Are the Latest Data?

CME/CNE

Thursday, May 30, 2024 | 12:00 pm - 12:30 pm ET
Supported by an independent educational grant from BioMarin.

overview

Join us for a live webinar featuring 2 world-renowned experts discussing the latest clinical data on current and emerging gene therapies for hemophilia A. After a detailed review of updated safety and efficacy data presented at recent medical congresses, the program will feature expert analysis on integrating new information into clinical practice. The audience will have an opportunity to submit questions for discussion by the expert faculty.

faculty

SPEAKER

Steven W. Pipe, MD

Professor of Pediatrics and Pathology

Pediatric Medical Director

Hemophilia and Coagulation Disorders Program

Director, Special Coagulation Laboratory

University of Michigan

Ann Arbor, Michigan, United States

SPEAKER

Margareth C. Ozelo, MD, PhD

Associate Professor, Internal Medicine

Director, Haematology

Hemocentro UNICAMP

University of Campinas

Campinas, São Paulo, Brazil

AGENDA

Welcome and Introduction

Steven W. Pipe, MD

Efficacy and Safety of Gene Therapies for Hemophilia A: An Overview and Review of Recent Data

Margareth C. Ozelo, MD, PhD

Current Treatment Considerations for Hemophilia A Gene Therapies

Margareth C. Ozelo, MD, PhD

Q&A

All Faculty

Closing Remarks

Steven W. Pipe, MD

GOAL STATEMENT

The goal of this activity is for learners to be better able to define which patients are eligible for hemophilia A gene therapy and describe therapeutic expectations according to the latest clinical data.

TARGET AUDIENCE

This activity is intended for hematologists, primary care clinicians, nurses, and other clinicians involved in the care of patients with hemophilia.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

  • Latest clinical data evaluating gene therapies for hemophilia A
  • Eligibility considerations for hemophilia A gene therapies

Have greater competence related to

  • Integrating recent findings on long-term safety and efficacy of gene therapies for hemophilia A

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo

For Physicians

Medscape, LLC designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs.

medscapelive
© 2024 MedscapeLIVE! All Rights Reserved | Terms of Service | Privacy Policy